Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021
HomeGamma MedicaGamma Medica Announces Pennsylvania’s First Clinical Installation of LumaGEM® Molecular Breast Imaging...

Gamma Medica Announces Pennsylvania’s First Clinical Installation of LumaGEM® Molecular Breast Imaging System at Einstein Medical Center Philadelphia


Secondary screening method significantly improves early cancer detection for women with dense breast tissue

Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has installed Pennsylvania’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection of breast cancer in women.1

In the U.S., approximately 50 percent of women are reported to have dense breast tissue, but many women do not realize they have dense breasts or the implications dense breast tissue has on increasing their lifetime risk of breast cancer.2 Dense breast tissue and cancer both appear white on mammograms making it difficult to distinguish between the two. It’s like trying to find a snowflake in a snowstorm, which can lead to false negatives or delayed diagnoses.3

Philip Croxford, president and CEO of Gamma Medica highlights, The new installation of the LumaGEM MBI system at Einstein Medical Center Philadelphia now gives women access to a clinically superior diagnostic and secondary breast screening method.  He went on to say,  “LumaGEM MBI provides the opportunity for personalized breast screenings in women who are at higher risk of being diagnosed with breast cancer, in effect raising the standard in breast cancer detection. We look forward to continued collaboration with the hospital and its affiliates with the goal of improving the lives of women in the area.”

A breakthrough retrospective clinical study published in the August issue of the American Journal of Roentgenologyconfirmed MBI’s high incremental cancer detection rate: MBI was able to detect 7.7 cancers per 1,000 women screened that were not found using mammography. Approximately 85 percent of these cancers were invasive and 82 percent of the invasive cancers were also node negative, meaning they were detected at an earlier stage and presented a better prognosis.4 While mammograms may fail to detect breast tumors due to tissue density, MBI highlights metabolic activity in these tumors despite breast density, leading to an earlier diagnosis.

“I’m excited about adding this technology to our program so we can help screen so many of our patients who have dense breast tissue,” said Debra Somers Copit, MD, director of breast imaging for Einstein Healthcare Network.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy